2
Clinical Trials associated with RNA CART-cMET(University of Pennsylvania) / TerminatedEarly Phase 1IIT Clinical Trial of Autologous cMET Redirected T Cells Administered Intravenously in Patients With Melanoma & Breast Carcinoma
This is a pilot study to evaluate feasibility, safety, and preliminary evidence of efficacy for intravenously administered, RNA electroporated autologous T cells expressing MET chimeric antigen receptors with tandem TCRζ and 4-1BB (TCRζ /4-1BB) co-stimulatory domains (referred to as "RNA CART-cMET") in patients with advanced melanoma or breast carcinoma.
Clinical Trial of Autologous cMet Redirected T Cells Administered Intratumorally in Patients With Breast Cancer
An open-label, clinical trial of autologous cMet redirected T cells administered intratumorally (IT) in patients with breast cancer. Fifteen evaluable patients will be enrolled in stepwise fashion. Step 1 will enroll patients with metastatic breast cancer refractory to at least 1 standard therapy, step 2 will include newly diagnosed patients with operable triple negative breast cancer.
100 Clinical Results associated with RNA CART-cMET(University of Pennsylvania)
100 Translational Medicine associated with RNA CART-cMET(University of Pennsylvania)
100 Patents (Medical) associated with RNA CART-cMET(University of Pennsylvania)
100 Deals associated with RNA CART-cMET(University of Pennsylvania)